Is Denali Therapeutics (DNLI) Still Undervalued On Its Mixed Valuation Signals?

Denali Therapeutics (DNLI) drew fresh attention after recent trading left the stock about 11% lower over the past month, despite a gain of roughly 7% over the past 3 months.

Recent trading paints a mixed picture for Denali Therapeutics. Short-term momentum is fading with a 7-day share price return of 5.09% and a 30-day move down 11.08%. However, the year-to-date share price return of 35.71% and 1-year total shareholder return of 43.75% still point to a stock that has rewarded patient holders, even as longer 3 and 5-year total shareholder returns remain weak.

Scan beyond Denali Therapeutics and see how other biopharma stocks with momentum and quality screens stack up using our hand-picked 17 high quality undiscovered gems.

After a sharp year-to-date rebound followed by a pullback, Denali Therapeutics now sits at a crossroads. Is most of the rerating already in the rear-view mirror, or is meaningful upside still on the table when you run the numbers?

Most Popular Narrative: 37.7% Undervalued

Against a last close of $22.08, the most followed Denali Therapeutics narrative anchors on a fair value of $35.44, which implies a large valuation gap if its assumptions hold.

The enzyme transport vehicle franchise targets multiple lysosomal storage disorders where biologics are already an accepted treatment class. Denali Therapeutics expects each program to represent several hundred million dollars or more in potential annual market opportunity, which can influence long term revenue diversification and earnings resilience.

Read the complete narrative. Read the complete narrative.

Curious what has to go right to support that kind of upside for Denali Therapeutics? The narrative leans on rapid revenue expansion, margin repair, and a rich future earnings multiple that many investors usually associate with high growth leaders. The key is how those ingredients combine over time and what that implies for today’s share price.

Result: Fair Value of $35.44 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the bullish Denali Therapeutics story hinges on AVLAYAH sustaining prescriptions in a small Hunter syndrome pool and on costly Alzheimer’s projects clearing key clinical hurdles.

Find out about the key risks to this Denali Therapeutics narrative.

Another View on Denali Therapeutics’ Valuation

The analyst narrative presents Denali Therapeutics as 37.7% undervalued at $35.44 per share, yet the Simply Wall St DCF model tells a different story. On that cash flow view, an estimated value of $18.40 sits below the current $22.28 quote, which points to an overvalued reading instead.

When two frameworks disagree this sharply, it puts the focus back on you. Which set of assumptions about future cash generation feels more realistic for Denali Therapeutics over the next decade, and how much risk are you comfortable tying to that view?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment around Denali Therapeutics is split, with clear concerns sitting alongside genuine optimism. Move quickly, review the data for yourself, and weigh the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Denali Therapeutics?

If Denali Therapeutics has you thinking more broadly about opportunities, now is the time to widen your watchlist and pressure test your next moves with data.

• Target potential mispricings by running through the 49 high quality undervalued stocks that blend quality fundamentals with compressed expectations.
• Protect your downside by scanning a 83 resilient stocks with low risk scores that focuses on resilient balance sheets and lower volatility profiles.
• Unearth future contenders early by combing through a 22 elite penny stocks with strong financials that filters for stronger financials in this higher risk corner of the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com